-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Esperion Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2011 to 2023.
- Esperion Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$61.9M, a 24% decline year-over-year.
- Esperion Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$98.5M, a 55.7% increase year-over-year.
- Esperion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$209M, a 10.4% increase from 2022.
- Esperion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$234M, a 13.2% increase from 2021.
- Esperion Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$269M, a 87.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)